Lundbeck sees hope in re-analysis of failed Phase III desmoteplase stroke trial
This article was originally published in Scrip
A post-hoc analysis of the failed DIAS-2 Phase III study of Lundbeck's candidate for the treatment of ischaemic stroke, desmoteplase, suggests that the drug is effective in the sub-group of patients who suffered a serious stroke.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.